Pridopidine: Phase II data

Teva reported top-line data from the double-blind, international Phase II PRIDE-HD trial in 400 patients with HD showing that certain doses of oral pridopidine significantly improved disease progression as measured by total functional capacity (TFC) at week 52 vs. placebo in both the total patient population and in patients with early stage disease. Patients received placebo or twice-daily 45, 67.5, 90 or 112.5 mg pridopidine. The trial was originally designed to evaluate pridopidine’s effect on UHDRS-TMS at week 26, but was extended to 52 weeks to evaluate pridopidine’s effect on disease progression as measured by TFC after the company determined that the compound was primarily a sigma-1 receptor agonist. ...